Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936731 | 0.84 | HRH3 (0.41) | HRH3SLC6A2IRAK4PDK1 | |
| Hydrochloric Acid SCHEMBL27625653 | 0.77 | HRH3 (0.38) | HRH3SLC6A2IRAK4PDK1 | |
| SCHEMBL24717709 | 0.74 | EBP (0.35) | PDK1 | |
| SCHEMBL25704176 | 0.73 | EPHX2 (0.32) | — | |
| SCHEMBL20356301 | 0.72 | — | — | |
| SCHEMBL22300957 | 0.72 | HRH3 (0.33) | HRH3SLC6A2PDK1 | |
| SCHEMBL9935790 | 0.72 | HRH3 (0.41) | HRH3SLC6A2PDK1 | |
| SCHEMBL24718214 | 0.72 | EBP (0.36) | PDK1 | |
| SCHEMBL2302961 | 0.71 | — | — | |
| SCHEMBL11895879 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | HRH3 2399/4885SLC6A2 4655/4885IRAK4 1563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.